$XBI $115.79 +0.16%%
Covid Updates
$NVAX -7.1% World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine source
$NVAX -7.1% Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine. source
$BNTX -4.2% Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply. source
$MRNA -6.3% Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant. source
Pipeline Updates
$DBVT -2.5% DBV Technologies Provides Update on Investigational Viaskin™ Peanut source
$CTMX +0.9% CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71 source
$ACAD +5.2% Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) source
$ALDX -38.0% Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease source
$SRNE -3.8% Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors. source
$CFRX -1.2% Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRSA Bacteremia in Pediatric Populations Published in Clinical Infectious Diseases. source
$SMMT -48.0% Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection. source
$SCYX +6.2% BREXAFEMME® (ibrexafungerp tablets) Added to Major National Formulary, Providing Access for Millions More Commercially Insured Patients. source
$PTCT +2.9% Oral Splicing Modifiers that Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform. source
$PSTX +4.0% Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors. source
$BLUE +0.9% bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program. source
$TPTX +2.8% Turning Point Therapeutics Provides Regulatory Updates. source
$ZGNX +6.8% Zogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to Expand the Use of FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome. source
$UBX -5.0% UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of α-Klotho Program. source
$GLTO +1.6% Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022. source
$ICPT -2.7% Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH. source
$FGEN +0.2% FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program. source
$CHRS +5.5% Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh). source
$ETON -0.2% Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid). source
$APTO -7.3% Aptose Provides Update on APTO-253 Program. source
$CYTK +3.2% Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics. source
$MDWD -3.7% MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds. source
$EDIT +1.1% Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia. source
$CARA -1.9% Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection. source
$CMPI +10.5% Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using Vidutolimod. source
$LCTX +21.2% Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders. source
Business Updates
$JAGX +1.8% Jaguar Health’s Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company’s Focus on Rare Diseases & Orphan Drugs. source
Posted by FS/JM
Comments